Vol.27/No.5

Early evidence suggests a dual bispecific strategy may be able to move the needle forward for patients with platinum-resistant ovarian cancer or endometrial cancer.

Maurie Markman, MD, unpacks goals-of-care discussions in oncology.

During an Onclive Peer Exchange, panelists examined the utility of circulating tumor DNA in bladder cancer and other genitourinary malignancies.

Multicancer early detection testing has emerged as an exciting strategy to expand cancer screening.

Douglas Flora, MD, LSSBB, discusses how AI is helping oncologists keep up with an evolving field, reinvent care timelines, and connect with patients.

GATA2 variants retain enhancer activity, alter differentiation, and may link inflammation to hematologic malignancy risk.

Nicole Lamanna, MD, discusses the implications of the FDA approval of frontline acalabrutinib plus venetoclax in CLL.

John L. Marshall, MD, and Christopher Lieu, MD, comment on the rising incidence of early-onset colorectal cancer (CRC) during CRC Awareness Month.